Heart Attack News and Research

RSS

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

A landmark international study, coordinated by McMaster University, has found that lower doses of a blood thinner called unfractionated heparin (UFH) during angioplasty did not reduce bleeding or vascular complications compared to standard dose UFH in patients initially treated with a blood thinner, fondaparinux.

31 Aug 2010

Outpatient prevention programme by nurses reduces risk of recurrent complications in heart patients

A six-month outpatient prevention programme conducted by nurses has resulted in significant and sustained improvements in the control of cardiovascular risk factors, including high cholesterol or high blood pressure, in patients hospitalised for a heart attack or impending heart attack.

31 Aug 2010

Social interaction reduces physical damage to brain by heart attack: Research

A new study in mice shows how social support can help minimize some of the worst physical damages to the brain caused by a heart attack.

31 Aug 2010

Bioheart's MyoCell adult stem cell therapy shows effective for heart failure patients: Study

Bioheart, Inc., The mission of the Cell Therapy Foundation is to improve public health through the support of effective adult stem cell research and education. The Foundation aims to promote basic and applied knowledge, processes and cell therapies.

31 Aug 2010

Peripheral arterial disease increases cardiovascular disease risk: Study

Most patients don't suspect a thing, and yet they are seriously ill: hardening of the arteries - peripheral arterial disease PAD - doubles the risk of premature death and serious cardiovascular events such as heart attack and stroke.

31 Aug 2010

African-Americans at higher risk of developing stent thrombosis

African-American race is a distinct risk factor for developing life-threatening blood clots after receiving a drug-coated stent, according to research reported in Circulation: Journal of the American Heart Association.

31 Aug 2010

Patients with atherothrombosis are at increased risk of ischemic events: Study

Clinical descriptors can assist clinicians in identifying patients with various stages of atherothrombosis (abnormal fatty deposits in an artery) who are at high-risk of future cardiovascular events, according to a study that will appear in the September 22 issue of JAMA. The study is being released early online to coincide with its presentation at the European Society of Cardiology meeting in Stockholm.

30 Aug 2010

MedCath to sell interest in Avera Heart Hospital of South Dakota to Avera McKennan

MedCath Corporation announced today it has entered into a definitive agreement to sell its subsidiary which is the indirect owner of a one-third ownership interest and management rights in Avera Heart Hospital of South Dakota to Avera McKennan. The transaction is expected to close in 45 to 90 days, subject to certain closing conditions.

30 Aug 2010

Large clinical trial does not confirm benefits of erythropoieitin for first ST-elevation myocardial infarction

Results from the HEBE III study, a prospective, randomised, multicentre trial performed in seven centres in the Netherlands, suggest that the promising effects of erythropoieitin seen in previous smaller studies cannot be confirmed for the improvement of clinical outcome in patients with a first ST-elevation myocardial infarction.

30 Aug 2010

New research contradicts previous reports on blood-thinner clopidogrel

New findings by McMaster University researchers contradict earlier reports that people with a certain genetic make-up don't benefit from the blood-thinner clopidogrel, also known as Plavix.

30 Aug 2010

ATOLL study favors enoxaparin over UFH for primary Percutaneous Coronary Intervention

The international ATOLL study sponsored by the Assistance Publique - Hopitaux de Paris showed that enoxaparin reduced the composite of death, complication of myocardial infraction, procedure failure or major bleeding by 17% in comparison with standard heparin death, recurrent acute coronary syndrome or urgent revascularisation. The results of the ATOLL study were presented at the hotline session of the annual European Cardiology Congress (ESC 2010) in Stockholm, Sweden.

30 Aug 2010

FDA approves Novartis' Tekamlo for treatment of high blood pressure

The US Food and Drug Administration (FDA) approved Tekamlo™ (aliskiren and amlodipine) tablets, a single-pill for the treatment of high blood pressure combining the only approved direct renin inhibitor, Tekturna® (aliskiren), with the widely used calcium channel blocker amlodipine. Tekamlo is approved as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals, and as replacement therapy for patients whose blood pressure is not adequately controlled with either aliskiren or amlodipine alone.

27 Aug 2010

New York State permits Genelex Corporation's DNA Drug Sensitivity Tests

The New York State Department of Health has licensed Genelex Corporation's DNA Drug Sensitivity Tests for use by doctors in the state. The issued Clinical Laboratory Permit is for DNA testing of three enzymes, the cytochrome P450s, that process more than 50 percent of the most commonly prescribed medicines.

27 Aug 2010

Researchers identify molecule to slow down dysfunctional immune response in hemorrhagic shock

Researchers have isolated a molecule, small enough to be used as a drug, that can shut down a dysfunctional immune response that causes deadly hemorrhagic shock, results in delayed death of heart attack patients, promotes rejection of transplanted organs and destroys joints in patients with rheumatoid arthritis, according to a paper published in Molecular Immunology.

27 Aug 2010

Researchers develop magnetic nanoparticles for metallic implant drug delivery

If a drug can be guided to the right place in the body, the treatment is more effective and there are fewer side-effects. Researchers at Lund University in Sweden have now developed magnetic nanoparticles that can be directed to metallic implants such as artificial knee joints, hip joints and stents in the coronary arteries.

26 Aug 2010

UNC Hospitals receives NCDR ACTION Registry-GWTG Silver Performance Achievement Award

UNC Hospitals has received the American College of Cardiology Foundation's NCDR ACTION Registry-GWTG Silver Performance Achievement Award for 2010 - one of only 26 hospitals nationwide to do so.

26 Aug 2010

Salinas Valley Memorial participates in trial of AngelMed Guardian System in high-risk heart patients

Imagine a day when you could be alerted to your impending heart attack before it happens. Research that got underway today at Salinas Valley Memorial Healthcare System could help that become a reality someday.

26 Aug 2010

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,781,168 relating to methods of determining heart attack risk by detecting the Ile4399Met genetic polymorphism in the protease-like domain of LPA.

25 Aug 2010

Statin therapy reduces cardiovascular disease risk in patients with high sensitivity C-reactive protein

People at intermediate risk of cardiovascular disease who have high levels of high sensitivity C-reactive protein (hsCRP), a blood marker for inflammation, could benefit from cholesterol-lowering therapy even if their cholesterol is already at desirable levels.

25 Aug 2010

Adoption of standby intra-aortic balloon pump strategy during high-risk PCI needed: Study

High-risk patients undergoing a coronary procedure such as placement of a stent who electively received an intra-aortic balloon pump (a device that can help improve blood flow) prior to the procedure did not experience a significantly lower overall rate of events such as heart attack, revascularization or death, according to a study in the August 25 issue of JAMA.

25 Aug 2010

Heart Attack News and Research

Standard dose of UFH optimal for treatment of PCI patients on fondaparinux: Study

Outpatient prevention programme by nurses reduces risk of recurrent complications in heart patients

Social interaction reduces physical damage to brain by heart attack: Research

Bioheart's MyoCell adult stem cell therapy shows effective for heart failure patients: Study

Peripheral arterial disease increases cardiovascular disease risk: Study

African-Americans at higher risk of developing stent thrombosis

Patients with atherothrombosis are at increased risk of ischemic events: Study

MedCath to sell interest in Avera Heart Hospital of South Dakota to Avera McKennan

Large clinical trial does not confirm benefits of erythropoieitin for first ST-elevation myocardial infarction

New research contradicts previous reports on blood-thinner clopidogrel

ATOLL study favors enoxaparin over UFH for primary Percutaneous Coronary Intervention

FDA approves Novartis' Tekamlo for treatment of high blood pressure

New York State permits Genelex Corporation's DNA Drug Sensitivity Tests

Researchers identify molecule to slow down dysfunctional immune response in hemorrhagic shock

Researchers develop magnetic nanoparticles for metallic implant drug delivery

UNC Hospitals receives NCDR ACTION Registry-GWTG Silver Performance Achievement Award

Salinas Valley Memorial participates in trial of AngelMed Guardian System in high-risk heart patients

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Statin therapy reduces cardiovascular disease risk in patients with high sensitivity C-reactive protein

Adoption of standby intra-aortic balloon pump strategy during high-risk PCI needed: Study

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News